Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary research data collected 1, 6, and 12 months after Dupixent’s launch. Along with awareness of, familiarity with, and perceptions related to Dupixent, this research assesses the trial and use, including anticipated future trends, of Dupixent. We also explore Sanofi/Regeneron’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other previously launched immune agents.
What you will learn in this content:
- What are U.S. dermatologists’ awareness of and familiarity with Dupixent, and what are their perceptions of the product?
- To which patients is Dupixent being prescribed, what are the reasons for prescribing it, and how satisfied are dermatologists with it?
- What promotional messages and activities are Sanofi and Regeneron using to support Dupixent’s launch?
- How do prescribers and nonprescribers compare across key metrics?
- How do the trial and adoption of Dupixent compare with the trial and adoption of other recent product launches for AD?
Methodology: ~75 U.S. dermatologists completed a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.
Key drugs: Dupixent
Key companies: Sanofi, Regeneron
Related reports: Atopic Dermatitis Disease Landscape and Forecast, Atopic Dermatitis Unmet Need, Access and Reimbursement – Atopic Dermatitis (US), Access and Reimbursement – Atopic Dermatitis (EU), Atopic Dermatitis Emerging Therapy Launch Tracking Eucrisa
- Atopic Dermatitis/Atopic Eczema - Emerging Therapies - Dupixent Launch Tracking Wave 3 (US)
- Dupixent Launch Tracking Wave 3 (US)
Author(s): Matthew W. Scutcher, MEng PhD; Emily Schriner, M.P.H.
Matthew Scutcher is Therapy Leader for the Immune & Inflammatory research team at DRG.
In this role, he leads a team of 13 Research Associates, Business Insights Analysts and Directors responsible for analyzing some of the largest and most dynamic markets in the pharmaceutical industry
He has been with DRG since 2009 and holds a Ph.D. from University College London and a Master’s degree in Chemical Engineering from Imperial College London.
Emily Schriner, M.P.H., is a business insights analyst on the Immune and Inflammatory Disorders team at DRG, part of Clarivate. She has authored several content pieces for immune market research reports and keeps the team up-to-date on the immune markets through research on patent life, pricing, and pipeline information. Ms. Schriner earned her master's degree in public health in nutrition at West Chester University of Pennsylvania. She completed an internship at Nemours Health Network in Wilmington, Delaware.